Advertisement
Australia markets open in 3 hours 12 minutes
  • ALL ORDS

    8,303.50
    +60.20 (+0.73%)
     
  • AUD/USD

    0.6732
    -0.0003 (-0.05%)
     
  • ASX 200

    8,057.90
    +58.60 (+0.73%)
     
  • OIL

    83.04
    +2.28 (+2.82%)
     
  • GOLD

    2,462.20
    -5.60 (-0.23%)
     
  • Bitcoin AUD

    95,998.93
    -345.39 (-0.36%)
     
  • CMC Crypto 200

    1,340.34
    -1.98 (-0.15%)
     

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed at $80.99 in the latest trading session, marking a +1.77% move from the prior day. The stock outpaced the S&P 500's daily loss of 0.16%. Meanwhile, the Dow lost 0.12%, and the Nasdaq, a tech-heavy index, lost 3.64%.

Heading into today, shares of the HIV and hepatitis C drugmaker had lost 1.62% over the past month, lagging the Medical sector's gain of 0.9% and the S&P 500's gain of 0.07% in that time.

Gilead Sciences will be looking to display strength as it nears its next earnings release. On that day, Gilead Sciences is projected to report earnings of $1.62 per share, which would represent a year-over-year decline of 23.58%. Meanwhile, our latest consensus estimate is calling for revenue of $6.43 billion, down 2.41% from the prior-year quarter.

For the full year, our Zacks Consensus Estimates are projecting earnings of $6.86 per share and revenue of $26.68 billion, which would represent changes of -5.51% and -2.2%, respectively, from the prior year.

ADVERTISEMENT

Investors might also notice recent changes to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.2% higher. Gilead Sciences is currently a Zacks Rank #3 (Hold).

Valuation is also important, so investors should note that Gilead Sciences has a Forward P/E ratio of 11.61 right now. This represents a discount compared to its industry's average Forward P/E of 19.44.

Investors should also note that GILD has a PEG ratio of 0.95 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.77 at yesterday's closing price.

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 89, which puts it in the top 36% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research